Alphabet Inc. holds a concentrated book of 26 stocks worth $4.0B as of Q1 2026 (disclosed May 8, 2026, a ~45-day 13F lag). This quarter they opened Cme Group Inc and trimmed Revolution Medicines Inc. Their largest long position is Cme Group Inc at 26% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1652044/holdings"
Use Arkolith to show Alphabet Inc.'s latest holdings, largest changes, and filing provenance.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Cme Group Inc COM | $1.0B | 3.48M | 25.6% | ▲New New position | |
| 2 | Planet Labs PBC COM CL A | $985.2M | 35.25M | 24.5% | ▲+10% Added · +3.3M sh | |
| 3 | Ast Spacemobile Inc COM CL A | $741.1M | 8.94M | 18.5% | —Held | |
| 4 | Revolution Medicines Inc COM | $320.2M | 3.29M | 8.0% | ▼−1.6% Reduced · −53K sh | |
| 5 | Arm Holdings PLC SPONSORED ADS | $296.6M | 1.96M | 7.4% | —Held | |
| 6 | Freshworks Inc CLASS A COM | $130.1M | 16.21M | 3.2% | —Held | |
| 7 | Uipath Inc CL A | $78.1M | 7.03M | 1.9% | —Held | |
| 8 | Tempus AI Inc CL A | $70.1M | 1.55M | 1.7% | —Held | |
| 9 | Paypay Corp SPONSORED ADS | $66.7M | 3.13M | 1.7% | ▲New New position | |
| 10 | Gitlab Inc CLASS A COM | $59.0M | 2.72M | 1.5% | —Held | |
| 11 | Prime Medicine Inc COM | $57.6M | 16.56M | 1.4% | —Held | |
| 12 | Ethos Technologies Inc CL A | $42.1M | 3.77M | 1.0% | ▲New New position | |
| 13 | Maze Therapeutics Inc COM | $41.4M | 1.39M | 1.0% | —Held | |
| 14 | Bridgebio Oncology Therapeut COM NEW | $25.3M | 2.82M | 0.6% | —Held | |
| 15 | Relay Therapeutics Inc COM | $15.6M | 1.56M | 0.4% | ▼−0.3% Reduced · −5K sh | |
| 16 | Monte Rosa Therapeutics Inc COM | $11.3M | 684.3K | 0.3% | ▼−8.1% Reduced · −61K sh | |
| 17 | Vera Therapeutics Inc CL A | $9.7M | 241.3K | 0.2% | —Held | |
| 18 | Sana Biotechnology Inc COM | $8.1M | 2.81M | 0.2% | —Held | |
| 19 | Beam Therapeutics Inc COM | $7.7M | 321.6K | 0.2% | —Held | |
| 20 | Lyell Immunopharma Inc COM NEW | $5.9M | 293.3K | 0.1% | —Held | |
| 21 | Oscar Health Inc CL A | $5.5M | 482.0K | 0.1% | —Held | |
| 22 | Figma Inc CLASS A COM STK | $4.6M | 215.6K | 0.1% | —Held | |
| 23 | Spero Therapeutics Inc COM | $2.1M | 890.0K | 0.1% | —Held | |
| 24 | Hyperfine Inc COM CL A | $971K | 898.7K | 0.0% | —Held | |
| 25 | Autolus Therapeutics PLC SPON ADS | $964K | 698.3K | 0.0% | —Held | |
| 26 | Tenaya Therapeutics Inc COM | $632K | 915.7K | 0.0% | —Held |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 8, 2026 | 27 | $4.0B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 13, 2026 | 32 | $2.6B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 7, 2025 | 40 | $2.4B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 1, 2025 | 39 | $2.1B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 2, 2025 | 44 | $1.6B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 7, 2025 | 44 | $1.7B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 8, 2024 | 46 | $1.8B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 2, 2024 | 46 | $2.0B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 3, 2024 | 47 | $2.5B | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 9, 2024 | 48 | $2.2B | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 13, 2023 | 51 | $1.6B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 4, 2023 | 56 | $1.9B | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 11, 2023 | 58 | $1.8B | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 61 | $1.7B | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 15, 2022 | 59 | $2.0B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Nov 15, 2022 | 65 | $1.8B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | Nov 15, 2022 | 70 | $3.1B | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Nov 15, 2022 | 67 | $4.1B | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 15, 2022 | 52 | $4.2B | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Nov 15, 2022 | 44 | $4.9B | 13F-HR |
| Q1 2021 | Mar 31, 2021 | Nov 15, 2022 | 37 | $2.5B | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Nov 15, 2022 | 33 | $2.1B | 13F-HR |
| Q3 2020 | Sep 30, 2020 | Nov 15, 2022 | 26 | $2.1B | 13F-HR |
| Q2 2020 | Jun 30, 2020 | Nov 15, 2022 | 26 | $2.2B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.